Dr. Brown on Idelalisib Plus Rituximab in CLL OncLive Jennifer Brown, MD, PhD, Director, Chronic Lymphocytic Leukemia Center, Dana-Farber Cancer Institute, Assistant Professor of Medicine, Harvard Medical School, discusses the development of the novel PI3K-delta inhibitor idelalisib as a treatment for ... |
